Lechleider Robert sold $1.2M of IMNM
Lechleider Robert (Chief Medical Officer) sold 55,000 shares of Immunome Inc. (IMNM) at an average of $22.62 ($21.95–$23.44, $1.24M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s post-transaction holdings (15,805 shares remaining) and confirms the trades were pre-arranged under Rule 10b5-1.
Market read
Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a fundamental repricing absent other catalysts.
What to watch
Without additional context (e.g., prior sale cadence, option exercises, or concurrent financing/clinical milestones), the signal-to-noise for trading is low.
Background
The article is a SEC Form 4 insider transaction by Immunome’s Chief Medical Officer, reported via EDGAR.
Ticker impact
Immunome CMO Lechleider Robert sold 55,000 shares in open-market trades totaling about $1.24M, under a 10b5-1 plan.
Likely limited near-term impact; any reaction should be muted given the stated 10b5-1 pre-arranged plan.
The filing is a Form 4 insider transaction with a disclosed 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling. The article provides no new company fundamentals beyond the sale details.
Market effects
Minimal; single insider sale in a biotech does not materially change sector fundamentals.
None indicated.
None indicated.
Counterpoint
The sale could be purely planned liquidity (10b5-1) and not a view on near-term prospects.
Key entities
- issuerImmunome Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderLechleider Robert
Chief Medical Officer who sold shares in open-market trades.